Yicura BioMed Advances Dual Capital and Industrial Strategy： Completes First Closing of Series B Financing Led by Gobi Partners
Résumé détaillé
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing…
The issuer is solely responsible for the content of this announcement.
Yicura BioMed ("Yicura") is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.
Founded in 2002, Gobi Partners is a leading pan-Asian investment firm specialising in bespoke capital solutions for family offices, sovereign wealth funds, financial institutions and corporate investors. Headquartered in Hong Kong and Kuala Lumpur, Gobi manages US$2 billion across 30+ investment vehicles, investing in early to growth-stage companies with the potential for generational and global impact. The firm's team of over 90 investment professionals operates from 18 locations, curating a diversified portfolio of more than 400 companies, with 76 exits achieved to date.
Début de l'article, extrait de Malay Mail. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.malaymail.com)
